Skip to main content

Table 3 Comparisons of cerebrospinal fluid soluble TREM2 levels between all disease groups and subgroups and controls

From: Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup

Groups compared

Mean (SEM) difference in CSF sTREM2 (ng/ml)

95% CI for CSF sTREM2 (ng/ml)

P value

Dementia vs. control

0.638 (0.806)

−0.966, 2.244

0.431

Clinical subgroups

 bvFTD vs. control

−0.349 (1.035)

−2.413, 1.713

0.736

 nfvPPA vs. control

0.544 (1.009)

−1.468, 2.556

0.592

 svPPA vs. control

1.145 (1.129)

−1.107, 3.397

0.314

 lvPPA vs. control

1.040 (1.037)

−1.025, 3.106

0.319

 PPA-NOS vs. control

1.840 (1.837)

−1.820, 5.502

0.320

 nfvPPA vs. bvFTD

0.305 (1.153)

−2.004, 2.615

0.792

 svPPA vs. bvFTD

1.344 (1.190)

−1.041, 3.729

0.264

 lvPPA vs. bvFTD

0.723 (1.224)

−1.730, 3.176

0.557

 PPA-NOS vs. bvFTD

1.228 (1.927)

−2.631, 5.088

0.526

 svPPA vs. nfvPPA

1.038 (1.247)

−1.460, 3.537

0.409

 lvPPA vs. nfvPPA

0.417 (1.101)

−1.789, 2.624

0.706

 PPA-NOS vs. nfvPPA

0.922 (1.939)

−2.961, 4.806

0.636

 lvPPA vs. svPPA

−0.621 (1.287)

−3.199, 1.957

0.631

 PPA-NOS vs. svPPA

−0.116 (2.016)

−4.154, 3.923

0.954

 PPA-NOS vs. lvPPA

0.505 (1.967)

−3.343, 4.445

0.798

Genetic subgroups

 GRN vs. control

2.748 (1.161)

0.331, 5.163

0.028a

 MAPT vs. control

−2.230 (1.144)

−4.609, 0.149

0.065

 C9orf72 vs. control

−1.897 (1.266)

−4.529, 0.735

0.149

 GRN vs. MAPT

4.978 (1.483)

1.893, 8.063

0.003a

 GRN vs. C9orf72

4.644 (1.536)

1.448, 7.840

0.006a

 C9orf72 vs. MAPT

0.334 (1.408)

−2.595, 3.262

0.815

Pathological subgroups

 AD biomarker-positive dementia vs. controls

1.921 (0.996)

−0.062, 3.905

0.057

 AD biomarker-negative dementia vs. controls

0.183 (0.817)

−1.446, 1.812

0.823

 AD biomarker-positive dementia vs. AD biomarker-negative dementia

F(2,58) = 3.77, P = 0.029a,b

  1. See list of abbreviations for definition of abbreviations
  2. Mean differences and 95% CIs are β values arising from multivariable linear regressions, adjusted for age and sex (disease groups and subgroups vs. controls), or age, sex and disease duration (between disease groups or subgroups, except for between genetic subgroups, which were adjusted for age and sex). Dementia group includes all individuals with FTD (bvFTD and PPA)
  3. aSignificant at P < 0.05
  4. bDifference between groups changes with varying disease duration; results of regression analysis comparing groups overall are presented, rather than specific value for mean difference
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193